Search

Your search keyword '"Bartkowiak, D."' showing total 245 results

Search Constraints

Start Over You searched for: Author "Bartkowiak, D." Remove constraint Author: "Bartkowiak, D."
245 results on '"Bartkowiak, D."'

Search Results

3. Adjuvante Strahlentherapie beim lymphknotenpositiven Prostatakarzinom mit geringer Tumorlast nach radikaler Prostatektomie: Multizentrische randomisierte Phase-III-Studie zur Wirkung einer adjuvanten Strahlentherapie bei Patienten mit Prostatakarzinom mit oder ohne positiven Schnittrand nach radikaler Prostatektomie (RP) und Lymphknotenmetastasierung mit geringer Tumorlast (Mikrometastasen, ≤ 2 Lymphknotenmakrometastasen). ART-2 – Studie AP 61/10 der AUO

4. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics

5. Toxicity profile of immediate post-prostatectomy radiation therapy: results from a large multi-institutional series

9. Adjuvante Strahlentherapie beim lymphknotenpositiven Prostatakarzinom mit geringer Tumorlast nach radikaler Prostatektomie: Multizentrische randomisierte Phase-III-Studie zur Wirkung einer adjuvanten Strahlentherapie bei Patienten mit Prostatakarzinom mit oder ohne positiven Schnittrand nach radikaler Prostatektomie (RP) und Lymphknotenmetastasierung mit geringer Tumorlast (Mikrometastasen, ≤ 2 Lymphknotenmakrometastasen). ART-2-Studie AP 61/11 der AUO

11. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: The key role of PSA kinetics

12. PSA doubling time as predictor of relapse after early salvage radiation therapy: When should imaging be used to select patients who might not benefit from early local treatments?

13. Verbundprojekt ESKaRa

14. The key role of PSA doubling time in patients treatedwith salvage radiation therapy after radical prostatectomy: implications for the extent of radiation and the concomitant use of hormonal therapy

15. Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treatedwith post-prostatectomy radiation therapy: results from a large, multi-institutional study

16. Very long term outcomes, time patterns of recurrence and other-cause mortality in patients treated with salvage radiation therapy for recurrent prostate cancer after radical prostatectomy: implications for risk tailored follow-up strategies

17. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 prostate cancer? Results form a large multi-institutional series

18. There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy. a retrospective, multi-centre analyses on oncological and toxicity outcomes

22. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 Prostate Cancer? Results form a large Multi-Institutional series

23. The key role of PSA doubling time in patients treated with salvage radiation therapy after radical prostatectomy: Implications for the extent of radiation and the concomitant use of hormonal therapy

24. Very long-term outcomes, time patterns of recurrence and other-cause mortality in patients treated with salvage radiation therapy for recurrent prostate cancer after radical prostatectomy: Implications for risk tailored follow-up strategies

25. Comparison of salvage radiation therapy delivered for PSA persistence versus PSA relapse after radical prostatectomy: How is the outcome changing?

26. Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treated with post-prostatectomy radiation therapy: Results from a large, multi-institutional study

29. Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series

30. Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series

31. Changing patterns and predictors of salvage radiation therapy use over time in patients treated for post-prostatectomy biochemical recurrence: a trend analysis over a 20-year period from a multi institutional series

32. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series

33. Cure without toxicity: development of a novel model predicting trifecta outcomes after salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

34. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: A stage-specific analysis from a large multi-institutional series

35. Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series

36. EAU BCR risk classification as decision tool for salvage radiatiotherapy

40. SC94 - Toxicity profile of immediate post-prostatectomy radiation therapy: results from a large multi-institutional series

41. SC93 - Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics

42. PT079 - Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study

43. A0194 - PSA doubling time as predictor of relapse after early salvage radiation therapy: When should imaging be used to select patients who might not benefit from early local treatments?

44. A0185 - Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: The key role of PSA kinetics

45. Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

46. There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy

47. Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

48. What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series

49. There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy

50. SC201 - The key role of PSA doubling time in patients treatedwith salvage radiation therapy after radical prostatectomy: implications for the extent of radiation and the concomitant use of hormonal therapy

Catalog

Books, media, physical & digital resources